Skip to main content
OpenTrials
Completed

NCT Number: NCT07064720

Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure

Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dexmedetomidine

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

facility of medicine Cairo university

Cairo, 12613, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

ASA I-II Patients scheduled for elective robot-assisted laparoscopic prostatectomy

Exclusion criteria

  • • ASA physical status > II
  • Cardiac patients
  • Cerebrovascular disease
  • Glaucoma
  • Hepatic failure
  • Renal failure
  • History of anaphylactic reaction to dexmedetomidine or mannitol
  • Hemodynamic instability
  • Cannot measure ONSD for example due to ophthalmological problems.
  • Any cause of preoperative increase in ICP for example intracranial space occupying lesions.

Treatment and study plan

Dexmedetomidine with Mannitol

Drug

receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol

Mannitol (20%)

Drug

receive 0.5 g/kg of mannitol

Primary outcomes

  1. optic nerve sheath diameter

    Time frame: 90 minutes

Secondary outcomes

  1. Postoperative neurologic complications

    Time frame: 24 HOURS

  2. Postoperative cardiac complications

    Time frame: 24 hours

  3. Duration of hospital stay

    Time frame: 30 days

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jul 15, 2025
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.